Global Hereditary Cancer Testing Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 142997
- Pages: 225
-
Format:
Short Description
Global Hereditary Cancer Testing Market, By Test Type (Multi Panel Set, and Single-Site Genetic Test) Diagnosis Type (Biopsy, Imaging, Lab Tests) Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray) Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Vol-Hippel Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes) End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others) Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of the Middle East and Africa, Brazil, Argentina, and Rest of South America) Industry Trends and Forecast to 2029
Market Definition
Hereditary cancer is any cancer caused by an inherited genetic mutation. Harmful variants in certain genes are associated with an increased risk of cancer. Genetic testing can estimate a person's lifetime risk of developing cancer. This can be done by looking for mutations in their genes, chromosomes, or proteins. Genetic testing is available for several types of cancer. These include breast, ovarian, colon, thyroid, prostate, pancreatic, skin cancer, sarcoma, and kidney and stomach cancer. Numerous medical studies show that 5% to 10% of common cancers are considered hereditary. Genetic tests are performed to determine whether a person carries a harmful genetic variant. These tests also help determine if a family member who has not yet had cancer has inherited the same variant as a family member known to have a cancer susceptibility alternative. Market Segmentation
The global hereditary cancer testing market is segmented into six notable segments based on test type, diagnosis type, technology, disease type, end user, and distribution channel.
On the basis of test type, the global hereditary cancer testing market is segmented into multi panel test and single-site genetic test
On the basis of diagnosis type, the global hereditary cancer testing market is segmented into biopsy, imaging, and lab tests
On the basis of technology, the global hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray
On the basis of disease type, the global hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome
On the basis of end user, the global hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others
On the basis of distribution channel, the global hereditary cancer testing market is segmented into direct tender, and retail sales
Market Players
Some of the major players operating in the global hereditary cancer testing market are:
Invitae Corporation
Illumina Inc.
Natera, Inc.
CENTOGENE N.V.
4baseCare
Biocartis
Fulgent Genetics
Ambry Genetics
BioReference
PerkinElmer Inc.
LifeLabs
Abbott
BIO-HELIX
Cepheid
Eurofins Scientific
TABLE OF CONTENTS
1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 OVERVIEW OF THE GLOBAL HEREDITARY CANCER TESTING MARKET 32
1.4 CURRENCY AND PRICING 34
1.5 LIMITATIONS 34
1.6 MARKETS COVERED 35
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 DBMR TRIPOD DATA VALIDATION MODEL 41
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.6 MULTIVARIATE MODELLING 45
2.7 MARKET END USER COVERAGE GRID 46
2.8 SOURCE LIFELINE CURVE 47
2.9 DBMR MARKET POSITION GRID 48
2.10 VENDOR SHARE ANALYSIS 50
2.11 SECONDARY SOURCES 51
2.12 ASSUMPTIONS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHT 56
4.1 PESTEL ANALYSIS 58
4.2 PORTERS FIVE FORCES 59
5 GLOBAL HEREDITARY CANCER TESTING MARKET: REGULATIONS 60
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER 67
6.1.2 INCREASE IN THE GERIATRIC POPULATION 67
6.1.3 RISING HEALTHCARE SPENDING 68
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING 68
6.2 RESTRAINTS 69
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING 69
6.2.2 LACK OF SKILLED PROFESSIONALS 70
6.3 OPPORTUNITIES 70
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 70
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 71
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 72
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES 72
6.4 CHALLENGES 73
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING 73
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS 74
7 GLOBAL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE 75
7.1 OVERVIEW 76
7.2 MULTI PANEL TEST 79
7.3 SINGLE-SITE GENETIC TEST 79
8 GLOBAL HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE 80
8.1 OVERVIEW 81
8.2 BIOPSY 84
8.2.1 NEEDLE BIOPSIES 84
8.2.2 ENDOSCOPIC BIOPSIES 84
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY 85
8.2.4 LAPAROTOMY AND THORACOTOMY 85
8.2.5 OTHERS 85
8.3 IMAGING 85
8.3.1 MAGNETIC RESONANCE IMAGING (MRI) 86
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN 86
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 86
8.3.4 NUCLEAR SCAN 86
8.3.5 ULTRASOUND 86
8.3.6 X-RAYS 86
8.4 LAB TESTS 87
8.4.1 BLOOD 87
8.4.2 URINE 87
8.4.3 OTHERS 87
9 GLOBAL HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY 88
9.1 OVERVIEW 89
9.2 POLYMERASE CHAIN REACTION (PCR) 92
9.3 SEQUENCING 92
9.4 MICRO ARRAY 93
10 GLOBAL HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE 94
10.1 OVERVIEW 95
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME 98
10.3 COWDEN SYNDROME 98
10.4 LYNCH SYNDROME 99
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME 99
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 100
10.7 LI-FRAUMENI SYNDROME 100
10.8 VON HIPPEL-LINDAU DISEASE 101
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME 101
11 GLOBAL HEREDITARY CANCER TESTING MARKET, BY END USER 102
11.1 OVERVIEW 103
11.2 HOSPITALS 106
11.3 CLINICS 106
11.4 DIAGNOSTIC CENTERS 107
11.5 RADIOLOGY CENTERS 107
11.6 LABORATORIES 108
11.7 OTHERS 108
12 GLOBAL HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL 109
12.1 OVERVIEW 110
12.2 DIRECT TENDER 113
12.3 RETAIL SALES 113
13 GLOBAL HEREDITARY CANCER TESTING MARKET, BY REGION 114
13.1 OVERVIEW 115
13.2 ASIA-PACIFIC 120
13.2.1 CHINA 128
13.2.2 JAPAN 132
13.2.3 SOUTH KOREA 136
13.2.4 INDIA 140
13.2.5 AUSTRALIA 144
13.2.6 SINGAPORE 148
13.2.7 THAILAND 152
13.2.8 MALAYSIA 156
13.2.9 INDONESIA 160
13.2.10 PHILIPPINES 164
13.2.11 REST OF ASIA-PACIFIC 168
13.3 NORTH AMERICA 169
13.3.1 U.S. 176
13.3.2 CANADA 180
13.3.3 MEXICO 184
13.4 EUROPE 188
13.4.1 GERMANY 196
13.4.2 FRANCE 200
13.4.3 U.K. 204
13.4.4 RUSSIA 208
13.4.5 ITALY 212
13.4.6 SPAIN 216
13.4.7 TURKEY 220
13.4.8 NETHERLANDS 224
13.4.9 SWITZERLAND 228
13.4.10 BELGIUM 232
13.4.11 REST OF EUROPE 236
13.5 SOUTH AMERICA 237
13.5.1 BRAZIL 244
13.5.2 ARGENTINA 248
13.5.3 REST OF SOUTH AMERICA 252
13.6 MIDDLE EAST AND AFRICA 253
13.6.1 SOUTH AFRICA 261
13.6.2 SAUDI ARABIA 265
13.6.3 U.A.E. 269
13.6.4 EGYPT 273
13.6.5 ISRAEL 277
13.6.6 REST OF THE MIDDLE EAST AND AFRICA 281
14 GLOBAL HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE 282
14.1 COMPANY SHARE ANALYSIS: GLOBAL 282
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 283
14.3 COMPANY SHARE ANALYSIS: EUROPE 284
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 285
15 SWOT ANALYSIS 286
16 COMPANY PROFILE 287
16.1 ABBOTT 287
16.1.1 COMPANY SNAPSHOT 287
16.1.2 REVENUE ANALYSIS 287
16.1.3 COMPANY SHARE ANALYSIS 288
16.1.4 PRODUCT PORTFOLIO 288
16.1.5 RECENT DEVELOPMENTS 288
16.2 ILLUMINA, INC. (2021) 289
16.2.1 COMPANY SNAPSHOT 289
16.2.2 REVENUE ANALYSIS 289
16.2.3 COMPANY SHARE ANALYSIS 290
16.2.4 PRODUCT PORTFOLIO 290
16.2.5 RECENT DEVELOPMENTS 291
16.3 PERKINELMER INC. (2021) 292
16.3.1 COMPANY SNAPSHOT 292
16.3.2 REVENUE ANALYSIS 292
16.3.3 COMPANY SHARE ANALYSIS 293
16.3.4 PRODUCT PORTFOLIO 293
16.3.5 RECENT DEVELOPMENTS 293
16.4 LIFELABS GENETICS 294
16.4.1 COMPANY SNAPSHOT 294
16.4.2 COMPANY SHARE ANALYSIS 294
16.4.3 PRODUCT PORTFOLIO 295
16.4.4 RECENT DEVELOPMENTS 295
16.5 EUROFINS SCIENTIFIC (2021) 296
16.5.1 COMPANY SNAPSHOT 296
16.5.2 REVENUE ANALYSIS 296
16.5.3 COMPANY SHARE ANALYSIS 297
16.5.4 PRODUCT PORTFOLIO 297
16.5.5 RECENT DEVELOPMENT 297
16.6 AMBRY GENETICS 298
16.6.1 COMPANY SNAPSHOT 298
16.6.2 REVENUE ANALYSIS 298
16.6.3 PRODUCT PORTFOLIO 299
16.6.4 RECENT DEVELOPMENTS 299
16.7 BIOCARTIS 300
16.7.1 COMPANY SNAPSHOT 300
16.7.2 REVENUE ANALYSIS 300
16.7.3 PRODUCT PORTFOLIO 301
16.7.4 RECENT DEVELOPMENTS 301
16.8 BIO-HELIX 302
16.8.1 COMPANY SNAPSHOT 302
16.8.2 PRODUCT PORTFOLIO 302
16.8.3 RECENT DEVELOPMENTS 302
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021) 303
16.9.1 COMPANY SNAPSHOT 303
16.9.2 REVENUE ANALYSIS 303
16.9.3 PRODUCT PORTFOLIO 304
16.9.4 RECENT DEVELOPMENT 304
16.10 CENTOGENE N.V. (2021) 305
16.10.1 COMPANY SNAPSHOT 305
16.10.2 REVENUE ANALYSIS 305
16.10.3 PRODUCT PORTFOLIO 306
16.10.4 RECENT DEVELOPMENT 306
16.11 CEPHEID 307
16.11.1 COMPANY SNAPSHOT 307
16.11.2 PRODUCT PORTFOLIO 307
16.11.3 RECENT DEVELOPMENT 307
16.12 FULGENT GENETICS 308
16.12.1 COMPANY SNAPSHOT 308
16.12.2 REVENUE ANALYSIS 308
16.12.3 PRODUCT PORTFOLIO 309
16.12.4 RECENT DEVELOPMENT 309
16.13 INVITAE CORPORATION 310
16.13.1 COMPANY SNAPSHOT 310
16.13.2 REVENUE ANALYSIS 310
16.13.3 PRODUCT PORTFOLIO 311
16.13.4 RECENT DEVELOPMENT 311
16.14 NATERA, INC. (2021) 312
16.14.1 COMPANY SNAPSHOT 312
16.14.2 REVENUE ANALYSIS 312
16.14.3 PRODUCT PORTFOLIO 313
16.14.4 RECENT DEVELOPMENTS 313
16.15 4BASECARE. 315
16.15.1 COMPANY SNAPSHOT 315
16.15.2 PRODUCT PORTFOLIO 315
16.15.3 RECENT DEVELOPMENTS 316
17 QUESTIONNAIRE 317
18 RELATED REPORTS 320
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
